TREATMENT OF OBSTRUCTIVE SLEEP APNEA SYNDROME BY DIAPHRAGM PACING STIMULATION IN A PATIENT WITH AMYOTROPHIC LATERAL SCLEROSIS

Obstructive sleep apnea syndrome (OSAS) is commonly seen in patients with neurological disorders, such as amyotrophic lateral sclerosis (ALS), especially later in disease course when diaphragmatic dysfunction and respiratory compromise becomes evident. The gold standard therapy of OSAS is the noninvasive mechanical ventilation (NIMV). The mainstay treatment for patients with ALS and respiratory disturbances is also accepted as NIMV to prolong life expectancy. Diaphragm pacing stimulation (DPS) has recently been introduced and suggested to be beneficial in patients with ALS. Here we report a patient with ALS, in whom OSAS was completely resolved upon DPS intervention. With more common application of diaphragmatic pacing in ALS patients with respiratory involvement will offer a supportive treatment rather than traditional palliative care

Rationale and Design of the Turkish Sleep Apnea Database - TURKAPNE: A National, Multicenter, Observational, Prospective Cohort Study

WOS: 000439590300008PubMed ID: 30083405OBJECTIVES: The primary aim of The Turkish Sleep Apnea Database (TURKAPNE) study is to generate a cross-sectional nationwide database for defining the clinical and polysomnographic characteristics of the patients with obstructive sleep apnea (OSA) in Turkey. MATERIALS AND METHODS: In this ongoing project, all consecutive adults with suspected OSA are recruited from the sleep centers of the university and research hospitals in Turkey. Information on anthropometric data, educational status, driving license, smoking habits, alcohol use, comorbidities, drug use, questionnaires, polysomnographic, and/or cardiorespiratory polygraphic findings are recorded in a systematized Web-based report form. Blood glucose, lipids and other biochemical markers, lung function, and echocardiography measurements are optionally included. Follow-up data regarding treatment modality and compliance is assessed. Cross-sectional and longitudinal associations between OSA phenotypes and metabolic, pulmonary, and cardiovascular comorbidities as well as traffic accidents, and the impact of treatment will be further explored. We target a total sample of 10,000 participants. RESULTS: The study was registered with ClinicalTrials.gov (NCT02784977) in May 2016 and the first patient was recruited in October 2017. A total of 1911 participants from 19 centers have been enrolled in the study by May 31, 2018. CONCLUSION: The TURKAPNE study will contribute to a better understanding of the health-related burden of OSA phenotypes and its association with the comorbidities and adverse outcomes, including traffic accidents in Turkey. The results may also contribute to a more personalized approach and better management of varying OSA phenotypes with concomitant disorders.Turkish Thoracic SocietyThe foundation and infrastructure of the database was supported by grants from the Turkish Thoracic Society with no influence on the design of the study, the analysis of the data, the data collection, drafting of the manuscript, or the decision to publish